Q2 EPS Forecast for Niagen Bioscience Increased by Analyst

Key Points

• Roth Capital raised its Q2 2026 EPS estimate for Niagen Bioscience to $0.04 per share, up from a previous forecast of $0.01, maintaining a "Buy" rating with a price target of $23.00.
• Niagen Bioscience reported Q2 earnings of $0.04 per share, exceeding the consensus estimate of $0.02, alongside a revenue of $31.12 million, surpassing expectations.
• Various brokerages have recently upgraded or adjusted their ratings on Niagen Bioscience, with the stock currently holding a consensus "Buy" rating and a price target around $13.22.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Analysts at Roth Capital raised their Q2 2026 earnings per share (EPS) estimates for Niagen Bioscience in a report issued on Thursday, August 7th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings of $0.04 per share for the quarter, up from their previous estimate of $0.01. Roth Capital has a "Buy" rating and a $23.00 price target on the stock.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Several other brokerages have also recently commented on NAGE. Wall Street Zen cut Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group boosted their price target on Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $13.22.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE opened at $9.73 on Monday. The stock has a market cap of $775.97 million, a price-to-earnings ratio of 46.34 and a beta of 2.12. The business has a 50 day simple moving average of $11.77 and a 200 day simple moving average of $8.30. Niagen Bioscience has a 52 week low of $2.69 and a 52 week high of $14.69.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently modified their holdings of NAGE. JPMorgan Chase & Co. raised its position in shares of Niagen Bioscience by 2.8% in the fourth quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company's stock valued at $1,810,000 after purchasing an additional 9,305 shares during the period. Geode Capital Management LLC raised its position in shares of Niagen Bioscience by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock valued at $6,128,000 after purchasing an additional 5,186 shares during the period. Trexquant Investment LP bought a new position in shares of Niagen Bioscience in the fourth quarter valued at approximately $144,000. Wells Fargo & Company MN grew its holdings in Niagen Bioscience by 42.1% in the 4th quarter. Wells Fargo & Company MN now owns 23,137 shares of the company's stock valued at $123,000 after buying an additional 6,856 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Niagen Bioscience by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock valued at $3,781,000 after buying an additional 288,588 shares during the last quarter. Institutional investors own 15.41% of the company's stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.